Scottish medical regulator approves MabThera as 'maintenance therapy' for lymphoma
THURSDAY 14 DECEMBER 2006
People in Scotland with a type of non-Hodgkin's lymphoma, who have relapsed, will get access to MabThera on the NHS following a decision by the Scottish Medicines Consortium (SMC). Commenting Kate Law, Cancer Research UK's director of clinical trials, said: "Cancer Research UK welcomes the SMC decision to recommend MabThera as 'maintenance therapy' for Scottish patients with a type of non Hodgkin's lymphoma who have relapsed. "MabThera is already approved throughout the UK as a first-line treatment in combination with other drugs for non Hodgkin's lymphoma but it was also recently licensed for use with these patients, and initial data suggest this may further increase survival.
"More clinical trials are ongoing, and we hope that NICE will reach the same conclusion when it considers this extended use of MabThera in the NHS in England and Wales as well."
Study shows many cancer survivors use complementary therapies
Half of suncreams provide inadequate protection
Removal of bacteria reduces risk of stomach cancer redeveloping
MicroRNAs may aid cancer detection
Impotence drugs make chemotherapy more effective in rats
Skin cancer fears may increase risk of bone thinning disease
New drug shows promise against aggressive prostate cancer in small trial
Cervical cancer vaccination programme to be extended
Food firms still marketing unhealthy products to children
Study finds little benefit from breast self-exams, but being 'breast-aware' is vital
